Applied Molecular Transport Inc. (AMTI)
NasdaqCM - NasdaqCM 即時價格。貨幣為 USD。
加入追蹤清單
收市：04:00PM EDT
收市後：
| 前收市價 | 0.1570 |
| 開市 | 0.1771 |
| 買盤 | 0.1754 x 900 |
| 賣出價 | 0.1850 x 900 |
| 今日波幅 | 0.1700 - 0.1844 |
| 52 週波幅 | 0.1510 - 1.3900 |
| 成交量 | |
| 平均成交量 | 1,063,315 |
| 市值 | 7.145M |
| Beta 值 (5 年，每月) | 2.06 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.1900 |
| 業績公佈日 | 2023年11月06日 - 2023年11月10日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 1.00 |
BenzingaApplied Molecular's Ulcerative Colitis Candidate Fails To Separate From Placebo In Untreated Patients
Applied Molecular Transport Inc (NASDAQ: AMTI) announced topline Phase 2 results from the LOMBARD monotherapy trial for AMT-101 in biologic-naïve and experienced patients with moderate-to-severe ulcerative colitis (UC). The clinical remission (CR) rate in patients treated with AMT-101 monotherapy was 17.1% (12/70 patients) compared to a CR rate of 20.0% (7/35 patients) with placebo, which was above the company's baseline assumption for placebo CR rates based on published data in moderate-to-seve
